These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30146958)

  • 1. Antibiotic Pipeline Coordinators.
    Baraldi E; Lindahl O; Savic M; Findlay D; Årdal C
    J Law Med Ethics; 2018 Jun; 46(1_suppl):25-31. PubMed ID: 30146958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics.
    Savic M; Årdal C
    J Law Med Ethics; 2018 Jun; 46(1_suppl):9-24. PubMed ID: 30146963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priority pathogens and the antibiotic pipeline: an update.
    Beyer P; Paulin S
    Bull World Health Organ; 2020 Mar; 98(3):151. PubMed ID: 32132745
    [No Abstract]   [Full Text] [Related]  

  • 4. (Inter)nationalising the antibiotic research and development pipeline.
    Singer AC; Kirchhelle C; Roberts AP
    Lancet Infect Dis; 2020 Feb; 20(2):e54-e62. PubMed ID: 31753765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mandatory surveillance and outbreaks reporting of the WHO priority pathogens for research & discovery of new antibiotics in European countries.
    Babu Rajendran N; Mutters NT; Marasca G; Conti M; Sifakis F; Vuong C; Voss A; Baño JR; Tacconelli E;
    Clin Microbiol Infect; 2020 Jul; 26(7):943.e1-943.e6. PubMed ID: 31812771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Product Development Partnership Model for Antibiotic Resistance.
    Billington JK
    Am J Law Med; 2016 May; 42(2-3):487-523. PubMed ID: 29086636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic development - economic, regulatory and societal challenges.
    Årdal C; Balasegaram M; Laxminarayan R; McAdams D; Outterson K; Rex JH; Sumpradit N
    Nat Rev Microbiol; 2020 May; 18(5):267-274. PubMed ID: 31745330
    [No Abstract]   [Full Text] [Related]  

  • 8. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
    Kelly R; Zoubiane G; Walsh D; Ward R; Goossens H
    Lancet Infect Dis; 2016 Apr; 16(4):431-40. PubMed ID: 26708524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The global preclinical antibacterial pipeline.
    Theuretzbacher U; Outterson K; Engel A; Karlén A
    Nat Rev Microbiol; 2020 May; 18(5):275-285. PubMed ID: 31745331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming the current deadlock in antibiotic research.
    Schäberle TF; Hack IM
    Trends Microbiol; 2014 Apr; 22(4):165-7. PubMed ID: 24698433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Together towards a common goal: REVIVE, a community of antimicrobial researchers brought together by the Global Antibiotic Research & Development Partnership (GARDP).
    Pentz-Murr A; Piddock LJV
    J Antimicrob Chemother; 2019 Jul; 74(7):1769-1770. PubMed ID: 30793751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All.
    Bhatti T; Lum K; Holland S; Sassman S; Findlay D; Outterson K
    J Law Med Ethics; 2018 Jun; 46(1_suppl):59-65. PubMed ID: 30146959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials.
    Walesch S; Birkelbach J; Jézéquel G; Haeckl FPJ; Hegemann JD; Hesterkamp T; Hirsch AKH; Hammann P; Müller R
    EMBO Rep; 2023 Jan; 24(1):e56033. PubMed ID: 36533629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives.
    Morel CM; Edwards SE
    J Law Med Ethics; 2018 Jun; 46(1_suppl):75-80. PubMed ID: 30146962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (Some) current concepts in antibacterial drug discovery.
    van Geelen L; Meier D; Rehberg N; Kalscheuer R
    Appl Microbiol Biotechnol; 2018 Apr; 102(7):2949-2963. PubMed ID: 29455386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ensuring Sustainability of Needed Antibiotics: Aiming for the DART Board.
    Spellberg B; Nielsen TB; Gilbert DN; Shorr AF; Brass EP
    Ann Intern Med; 2019 Oct; 171(8):580-582. PubMed ID: 31590184
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in Antibiotic R&D Calling for a Global Strategy Considering Both Short- and Long-Term Solutions.
    Kållberg C; Salvesen Blix H; Laxminarayan R
    ACS Infect Dis; 2019 Aug; 5(8):1265-1268. PubMed ID: 31144803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.